India Immuno-Oncology Drugs help in stimulating the patient's immune system to fight cancer. Growing availability and affordability of these drugs in India is increasing their adoption for cancer treatment. Key products include PD-1/PD-L1 inhibitors, CTLA-4 inhibitors and other immunomodulators that help boost the body's natural defenses against cancer cells.
The global India Immuno-Oncology Drugs Market is estimated to be valued at US$ 338.98 Mn in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising adoption of immunotherapies for cancer treatment is one of the key trends driving the growth of the India immuno-oncology drugs market. According to India's National Cancer Registry Programme, cancer burden in India is projected to increase multifold in coming decade. Immuno-oncology drugs offer several advantages over traditional cancer therapies as they stimulate patient's immune system in a natural way and results in long-lasting response. Promising clinical trial results of various immuno-oncology combinations and growing healthcare expenditure in India are also supporting the market growth. However, high costs of these drugs remain a key challenge.
Segment Analysis
Immuno-Oncology drugs can be broadly categorized into PD-1/PD-L1 inhibitors, CTLA-4 inhibitors, DR agonists, and interleukins. PD-1/PD-L1 inhibitors sub-segment currently dominates the India immuno-oncology drugs market due to its targeted mechanism of action that helps unleash the immune system of patients to recognize and attack cancer cells. Some of the approved drugs under this sub-segment are Nivolumab, Pembrolizumab, and Atezolizumab.
Key Takeaways
The global India Immuno-Oncology Drugs Market Growth is expected to witness high growth. The global India Immuno-Oncology Drugs Market is estimated to be valued at US$ 338.98 Mn in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period 2023 to 2030.
Regional analysis related content comprises Regional analysis related content: The Western region dominates the India immuno-oncology drugs market owing to the presence of advanced healthcare facilities and high awareness levels regarding targeted therapies among oncologists and patients in this region.
Key players related content comprises: Key players operating in the India immuno-oncology drugs market are Fort Dearborn, Multi Color Corporation, Mondi Group.
Check below related articles on this topic: https://www.newsanalyticspro.com/the-immuno-oncology-drugs-market-in-india-is-driven-by-rising-cancer/
Comments
0 comment